Get the Stockscreener App
118.61
2.88%
3.32
After Hours:
118.61
Biogen Inc stock is traded at $118.61, with a volume of 1.21M.
It is up +2.88% in the last 24 hours and down -17.37% over the past month.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
See More
Previous Close:
$115.29
Open:
$115.02
24h Volume:
1.21M
Relative Volume:
0.76
Market Cap:
$17.46B
Revenue:
$9.61B
Net Income/Loss:
$1.62B
P/E Ratio:
10.71
EPS:
11.07
Net Cash Flow:
$1.77B
1W Performance:
+4.61%
1M Performance:
-17.37%
6M Performance:
-37.43%
1Y Performance:
-38.28%
1-Day Range:
$114.66
$118.77
1-Week Range:
$112.18
$119.99
52-Week Range:
$110.03
$238.00
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
118.61 | 17.46B | 9.61B | 1.62B | 1.77B | 11.07 |
|
LLY
Lilly Eli Co
|
839.96 | 677.40B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
157.47 | 371.98B | 89.33B | 21.81B | 18.06B | 8.99 |
|
ABBV
Abbvie Inc
|
172.99 | 316.82B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
58.08 | 293.24B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
110.86 | 216.19B | 51.72B | 11.94B | 13.81B | 5.88 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Wedbush Estimates Biogen's Q1 Earnings (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Sold by Treasurer of the State of North Carolina - MarketBeat
Fmr LLC Acquires 376,356 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Sterling Capital Management LLC Boosts Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Wells Fargo & Company MN Has $16.98 Million Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Cerity Partners LLC Buys 14,306 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Global factor VIII deficiency treatment Market Generated - openPR.com
Biogen's (BIIB) "Hold" Rating Reiterated at Needham & Company LLC - MarketBeat
Leerink Partnrs Issues Negative Forecast for Biogen Earnings - MarketBeat
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union - TradingView
Neuberger Berman Group LLC Cuts Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Top Development & Construction Projects: Kendall Common – MIT’s Volpe Redevelopment & Biogen’s New Global HQ - Boston Real Estate Times
BMO Capital Adjusts Biogen Price Target to $128 From $139 - marketscreener.com
Leerink Partnrs Has Negative Outlook of Biogen Q2 Earnings - MarketBeat
Jump Financial LLC Has $14.46 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Phoenix Financial Ltd. Acquires New Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
FIL Ltd Sells 91,285 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Canada Post Corp Registered Pension Plan Takes Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Europe Approves Eisai-Biogen's Alzheimer's Drug 'Under Strict Conditions' After Initial Negative Opinion - Benzinga
EU authorizes Eisai-Biogen's drug for early Alzheimer's treatment - Reuters
European regulators OK Alzheimer's treatment Leqembi after initial doubts - MySA
LPL Financial LLC Sells 20,253 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi - Yahoo Finance
European regulators OK Alzheimer’s treatment Leqembi after initial doubts - AP News
EC authorises Eisai and Biogen’s lecanemab for Alzheimer’s - Yahoo Finance
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday - marketscreener.com
Wedbush Cuts Biogen Price Target to $121 From $135, Maintains Neutral Rating - MarketScreener
Causeway Capital Management LLC Purchases New Shares in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen, Genentech Set for June Trial Over MS Drug Royalties - USA Herald
Biogen, Eisai's Alzheimer's Drug Leqembi Approved in EU - MarketScreener
Bank of Montreal Can Sells 8,575 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
APG Asset Management US Inc. Buys New Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
FY2025 EPS Estimates for Biogen Reduced by Cantor Fitzgerald - MarketBeat
Leqembi Makes History as First EU-Approved Drug to Target Root Cause of Alzheimer’s Disease - geneonline.com
Biogen, Genentech Head To June Trial Over MS Drug Royalties - Law360
APG Asset Management N.V. Has $15.57 Million Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
First Foundation Advisors Raises Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Drug to Treat Underlying Causes of Alzheimer's Gets EU Marketing Approval - marketscreener.com
Leqembi®∇ (lecanemab) is the First Medicine that Slows - GlobeNewswire
Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union - Biogen
Breakthrough: First-Ever Drug to Slow Early Alzheimer's Gets EU Green Light - Stock Titan
Granulomatosis With Polyangiitis Market Predicted to See - openPR.com
Biogen, Eisai win EU nod for Alzheimer’s drug (BIIB:NASDAQ) - Seeking Alpha
Biogen (BIIB) Achieves EU Approval for Leqembi in Alzheimer's Tr - GuruFocus
Biogen (BIIB) Achieves EU Approval for Leqembi in Alzheimer's Treatment | BIIB Stock News - GuruFocus
Biogen : European Commission Grants Marketing Authorization for Leqembi® (lecanemab) - marketscreener.com
EU authorizes Eisai-Biogen’s drug for treatment of early Alzheimer’s disease - KFGO
EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease - marketscreener.com
Goldman Sachs Adjusts Biogen's Price Target to $219 From $245, Keeps Buy Rating - MarketScreener
Recombinant Therapeutic Antibodies And Proteins Market - openPR.com
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):